Results 11 to 20 of about 3,430 (200)

HSP90 Inhibitor PU-H71 in Combination With BH3-Mimetics in the Treatment of Acute Myeloid Leukemia [PDF]

open access: yesCurrent Issues in Molecular Biology, 2023
Targeting the molecular chaperone HSP90 and the anti-apoptotic proteins MCL1 and BCL2 may be a promising novel approach in the treatment of acute myeloid leukemia (AML).
Ulrike Bacher   +2 more
exaly   +8 more sources

The Anti-Myeloma Activity of a Novel Purine Scaffold HSP90 Inhibitor PU-H71 Is via Inhibition of Both HSP90A and HSP90B1 [PDF]

open access: yesJournal of Hematology and Oncology, 2010
Background Heat shock protein 90 (HSP90) inhibitors have emerged as a promising class of anti-cancer drugs in both solid and hematologic malignancies.
Saad Z Usmani   +2 more
exaly   +7 more sources

Epichaperome Inhibition by PU-H71-Mediated Targeting of HSP90 Sensitizes Glioblastoma Cells to Alkylator-Induced DNA Damage [PDF]

open access: yesCancers
Background: Targeted therapies have been largely ineffective against glioblastoma (GBM) owing to the tumor’s heterogeneity and intrinsic and adaptive treatment resistance.
Pratibha Sharma   +2 more
exaly   +5 more sources

PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond [PDF]

open access: yesFrontiers in Pharmacology
Heat shock protein 90 (HSP90) is a pivotal molecular chaperone with multifaceted roles in cellular health and disease. Herein, we explore how HSP90 orchestrates cellular stress responses, particularly through its partnership with heat shock factor 1 (HSF-
Sameh Saber   +16 more
doaj   +4 more sources

Synthesis and Evaluation of Cell-Permeable Biotinylated PU-H71 Derivatives as Tumor Hsp90 Probes [PDF]

open access: yesBeilstein Journal of Organic Chemistry, 2013
The attachment of biotin to a small molecule provides a powerful tool in biology. Here, we present a systematic approach to identify biotinylated analogues of the Hsp90 inhibitor PU-H71 that are capable of permeating cell membranes so as to enable the ...
Gabriela Chiosis   +2 more
exaly   +4 more sources

In Vitro Purging of Acute Lymphoblastic Leukemia (B-ALL) Cells with the Use of PTL, DMAPT, or PU-H71. [PDF]

open access: yesInt J Mol Sci
Acute lymphoblastic leukemia (ALL) is a hematopoietic disorder that mainly affects the child population, and it is characterized by the presence of lymphoid progenitor or precursor cells with different genetic alterations.
Ortiz-Reyes AE   +11 more
europepmc   +4 more sources

Mutation of Framework Residue H71 Results in Different Antibody Paratope States in Solution [PDF]

open access: yesFrontiers in Immunology, 2021
Characterizing and understanding the antibody binding interface have become a pre-requisite for rational antibody design and engineering. The antigen-binding site is formed by six hypervariable loops, known as the complementarity determining regions ...
Monica L. Fernández-Quintero   +4 more
doaj   +3 more sources

FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia [PDF]

open access: yesCurrent Issues in Molecular Biology
Targeting the FLT3 receptor and the IL-1R associated kinase 4 as well as the anti-apoptotic proteins MCL1 and BCL2 may be a promising novel approach in the treatment of acute myeloid leukemia (AML).
Katja Seipel   +3 more
doaj   +2 more sources

HSP90 inhibitörü PU-H71’in ve radyoterapi ile kombine uygulamasının metastatik meme kanseri üzerine etkisinin araştırılması [PDF]

open access: yes, 2016
HSP90 (Isı Şok Proteini 90) birçok hücresel proteinin stabilizasyonunu sağlamaktadır. Stresli durumlarda ekspresyonu artan HSP90 hücresel proteinleri degredasyondan korur. HSP90'nın ekspresyon profili normal ve malign hücrelerde farklılık göstermektedir.
Kale, Şule
core   +3 more sources

PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy

open access: yesPU-H71 a novel Hsp90 inhibitor as a potential cancer-specific sensitizer to carbon-ion beam therapy
PU-H71, a Heat shock protein 90 (Hsp90) inhibitor, has yielded therapeutic efficacy in many preclinical models and is currently in clinical trials. Carbon-ion radiotherapy (CIRT) has provided successful tumor control; however, there is still a room for ...
李 惠子   +15 more
core   +4 more sources

Home - About - Disclaimer - Privacy